Clinical trials: Hematopoietic
Acute Myeloid Leukemia
Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission
The purpose of this study is to evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (HCT) using uniform…
- Trial name
- AML_AlloHCT (NCT03337568)
- Testing
- allogeneic hematopoietic cell transplantation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Hematologic Cancer, Hematologic Malignancy
Intervention for Fatigue in HCT Recipients
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following…
- Trial name
- NCT05715047
- Testing
- CBT for Fatigue, Usual Care
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
Hematopoietic Stem Cell Transplant
Effects of Compassion Training to Patients Undergoing HSCT on Biological and Psychosocial Parameters
The hematopoietic stem cell transplant (HSCT) experience is emotionally and physically stressful for cancer patients who undergo this procedure.
- Trial name
- NCT03737084
- Testing
- CBCT Intervention
- Where
- 2 sites in Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
Multiple Myeloma
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma…
- Trial name
- CAREMM-006 (NCT06793449)
- Testing
- anti-BCMA CAR-T, ASCT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic and Lymphatic System Neoplasm
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT07025538
- Testing
- Best Practice, Biomarker Analysis, Biospecimen Collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- City of Hope Medical Center
Clostridium Difficile Infections, Stem Cell Transplant Complications
Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Clostridium difficile (CD) infection are an important cause of morbi-mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- VANCALLO (NCT05256693)
- Testing
- Vancomycin
- Volunteers
- 336 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematopoietic Stem Cell Mobilization
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia
Evaluation of the efficacy and safety of recombinant human thrombopoietin (rhTPO) at 300 U/kg/day for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients
- Trial name
- NCT06955858
- Testing
- Recombinant Human Thrombopoietin（rhTPO）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Autoimmune Diseases
Cancer as a complicATion in reCipients of Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease iNdiCation trEated in FRance and Canada?
Autologous Hematopoietic Stem Cell Transplantation (AHSCT) is a treatment option for several types of Autoimmune Disease (AD) in patients who remain active despite disease modifying therapies.
- Trial name
- CATCH CANCER (NCT06507800)
- Testing
- Observational cohort
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation
Seventy-five percent of patients treated with hematopoietic stem cell transplants survive one-year post-transplantation. However, this intensive treatment is associated with prolonged hospitalizations and significant…
- Trial name
- PrepAllo (NCT07341698)
- Testing
- Resistance training, Nutritional Support, Usual care
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematopoietic Stem Cell Transplant
Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation
The purpose of this research study is to perform a serial analysis of immune function using blood cells and sera obtained from patients after vaccination following hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT01581164
- Testing
- Influenza vaccine, Varicella vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Graft Versus Host Disease
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation…
- Trial name
- NCT01379209
- Testing
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regimmune Corporation
Atherosclerosis, Cardiovascular Diseases
The Role of Stem Cells on Immune Cells in the Development of Cardiovascular Diseases
An observational pilot proof-of-principle study. 15 patients with significant coronary artery disease and 15 matched controls. To investigate whether long-term activation of the innate immune system, named 'trained innate…
- Trial name
- ATHEROSTEM (NCT03172507)
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Non-Hodgkin's Lymphoma
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
High-dose chemotherapy and autologous stem-cell transplantation have an established role in the treatment of aggressive Non-Hodgkin's lymphoma (NHL) when refractory to first line chemotherapy or after relapse.
- Trial name
- Zevalin (NCT00463463)
- Testing
- 90Yttrium Ibritumomab Tiuxetan (Zevalin)
- Where
- Israel
- Sponsor
- Soroka University Medical Center
Mucopolysaccharidosis Disorders, Hurler Syndrome
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based…
- Conditions
- Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome
- Trial name
- NCT02171104
- Testing
- Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00110058
- Testing
- recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Total-body Irradiation, Hematopoietic Stem Cell Transplant
Radiation Biodosimetry in Children Undergoing Total Body Irradiation
The purpose of this study is to develop fecal tests that will determine the extent of radiation exposure in patients undergoing radiation treatment for cancer.
- Trial name
- NCT01337648
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical College of Wisconsin
Multiple Sclerosis
Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Our goal is the elucidation of the mechanisms of action of autologous hematopoietic stem cell transplant (HSCT) and immunoablation by high-dose cyclophosphamide in multiple sclerosis (MS).
- Trial name
- NCT00342134
- Testing
- Stem Cell Transplanataion
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Inherited Metabolic Disorders (IMD)
A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456
A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456
- Trial name
- IMD-002 (NCT04008849)
- Testing
- Safety and efficacy assessments
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Magenta Therapeutics, Inc.
Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
This is a phase 2, open label, single arm trial. This study aims to assess the efficacy and safety of menin inhibitor BN104 as maintenance therapy in patients with acute leukemia harboring specific genetic alterations who have…
- Conditions
- Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy, Acute Leukemia
- Trial name
- NCT07101497
- Testing
- BN104 monotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.